Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines

Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-α, IFN-β) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgenstern, Birgit, Michaelis, Martin, Baer, Patrick C., Doerr, Hans W., Cinatl, Jindrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2005
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092851/
https://www.ncbi.nlm.nih.gov/pubmed/15607755
http://dx.doi.org/10.1016/j.bbrc.2004.11.128
_version_ 1783510183252590592
author Morgenstern, Birgit
Michaelis, Martin
Baer, Patrick C.
Doerr, Hans W.
Cinatl, Jindrich
author_facet Morgenstern, Birgit
Michaelis, Martin
Baer, Patrick C.
Doerr, Hans W.
Cinatl, Jindrich
author_sort Morgenstern, Birgit
collection PubMed
description Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-α, IFN-β) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-β and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-β for the treatment of SARS.
format Online
Article
Text
id pubmed-7092851
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-70928512020-03-25 Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines Morgenstern, Birgit Michaelis, Martin Baer, Patrick C. Doerr, Hans W. Cinatl, Jindrich Biochem Biophys Res Commun Article Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-α, IFN-β) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-β and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-β for the treatment of SARS. Elsevier Inc. 2005-01-28 2004-12-08 /pmc/articles/PMC7092851/ /pubmed/15607755 http://dx.doi.org/10.1016/j.bbrc.2004.11.128 Text en Copyright © 2004 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Morgenstern, Birgit
Michaelis, Martin
Baer, Patrick C.
Doerr, Hans W.
Cinatl, Jindrich
Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
title Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
title_full Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
title_fullStr Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
title_full_unstemmed Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
title_short Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
title_sort ribavirin and interferon-β synergistically inhibit sars-associated coronavirus replication in animal and human cell lines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092851/
https://www.ncbi.nlm.nih.gov/pubmed/15607755
http://dx.doi.org/10.1016/j.bbrc.2004.11.128
work_keys_str_mv AT morgensternbirgit ribavirinandinterferonbsynergisticallyinhibitsarsassociatedcoronavirusreplicationinanimalandhumancelllines
AT michaelismartin ribavirinandinterferonbsynergisticallyinhibitsarsassociatedcoronavirusreplicationinanimalandhumancelllines
AT baerpatrickc ribavirinandinterferonbsynergisticallyinhibitsarsassociatedcoronavirusreplicationinanimalandhumancelllines
AT doerrhansw ribavirinandinterferonbsynergisticallyinhibitsarsassociatedcoronavirusreplicationinanimalandhumancelllines
AT cinatljindrich ribavirinandinterferonbsynergisticallyinhibitsarsassociatedcoronavirusreplicationinanimalandhumancelllines

Ejemplares similares